2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06D.01 Prognostic Evaluation by Using ctDNA in Patients with EGFR Mutated Resectable Lung Cancer

Pdf Summary

The study focuses on using circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with resectable EGFR-mutated non-small cell lung cancer (NSCLC). The management of these cancers typically involves surgery followed by adjuvant chemotherapy. This study investigates ctDNA's role in detecting minimal residual disease and predicting recurrence in stages I to III EGFR-mutated NSCLC post-resection.<br /><br />Patients were enrolled from Kanazawa University Hospital between January 2017 and May 2020, and ctDNA was analyzed using diagnostic tools like Digital Droplet PCR. The study retrospectively assessed patient characteristics, including EGFR mutation status and survival outcomes.<br /><br />Findings reveal that ctDNA is detectable preoperatively in approximately 26.1% of these patients. The detection rate increased with advancing pathological stage, particularly from Stage IB onward. Importantly, the presence of ctDNA correlated with shorter disease-free survival (DFS) and overall survival (OS), indicating it as a potential marker for poor prognosis.<br /><br />The research identifies that ctDNA and venous invasion are significant predictors for recurrence. Patients with neither ctDNA nor venous invasion showed no recurrence, advocating for personalized treatment planning based on these markers. The study aligns with previous research, which also reported the utility of ctDNA in early-stage lung cancer prognosis and recurrence prediction.<br /><br />For effective clinical application, combining ctDNA analysis with venous invasion assessment is recommended. Future studies are suggested to validate these findings in larger, multicentric cohorts, potentially influencing treatment regimens like the ADAURA regimen which could be considered based on ctDNA and venous invasion statuses. Overall, this research highlights ctDNA's potential in guiding the management and improving outcomes for patients with resectable EGFR-mutated NSCLC.

Asset Subtitle

Yuya Murase

Meta Tag

Speaker Yuya Murase

Topic Pathology and Biomarkers

Keywords

circulating tumor DNA

ctDNA

EGFR-mutated NSCLC

non-small cell lung cancer

prognostic biomarker

minimal residual disease

recurrence prediction

Digital Droplet PCR

disease-free survival

venous invasion